BIOMAT Database Logo BIOMAT Database Logo

The serum assay of soluble CD44 standard (sCD44-st), CD44 splice variant 5 (sCD44-v5), and CD44 splice variant 6 (sCD44-v6) in patients with cervical cancer. 1998

A Gadducci, and M Ferdeghini, and S Cosio, and C Annicchiarico, and A Fanucchi, and C Prontera, and R Bianchi, and A R Genazzani
Department of Gynecology and Obstetrics, University of Pisa, Italy.

The pretreatment serum levels of soluble CD44 standard (sCD44st), CD44 splice variant 5 (sCD44-v5), and CD44 splice variant 6 (sCD44-v6) were retrospectively measured in 37 patients with untreated cervical cancer and in 36 patients with benign gynecological diseases as controls. Median sCD44-st levels were significantly higher in patients with cervical cancer than in controls (547 ng/ml, range 244-880 ng/ml versus 400.5 ng/ml, range 217-723 ng/ml, p = 0.004), whereas sCD44-v5 and sCD44-v6 concentrations were significantly lower in the former (34 ng/ml, range 0-140 ng/ml versus 44 ng/ml, range 11-109 ng/ml, p = 0.038; and 37 ng/ml, range 1-191 ng/ml versus 52.5 ng/ml, range 11-173 ng/ml, p = 0.007, respectively). sCD44-st, sCD44-v5, and sCD44-v6 levels were not related to FIGO stage and histologic type. Moreover, among patients with stage Ib-IIa cervical cancer, the preoperative levels of these glycoproteins correlated with neither the common prognostic variables nor the clinical outcome. Therefore, the serum assay of sCD44-st, sCD44-v5, and sCD44-v6 seems to have no clinical relevance for the management of patients with cervical cancer.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010049 Ovarian Diseases Pathological processes of the OVARY. Disease, Ovarian,Diseases, Ovarian,Ovarian Disease
D002294 Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed) Carcinoma, Epidermoid,Carcinoma, Planocellular,Carcinoma, Squamous,Squamous Cell Carcinoma,Carcinomas, Epidermoid,Carcinomas, Planocellular,Carcinomas, Squamous,Carcinomas, Squamous Cell,Epidermoid Carcinoma,Epidermoid Carcinomas,Planocellular Carcinoma,Planocellular Carcinomas,Squamous Carcinoma,Squamous Carcinomas,Squamous Cell Carcinomas
D002583 Uterine Cervical Neoplasms Tumors or cancer of the UTERINE CERVIX. Cancer of Cervix,Cancer of the Cervix,Cancer of the Uterine Cervix,Cervical Cancer,Cervical Neoplasms,Cervix Cancer,Cervix Neoplasms,Neoplasms, Cervical,Neoplasms, Cervix,Uterine Cervical Cancer,Cancer, Cervical,Cancer, Cervix,Cancer, Uterine Cervical,Cervical Cancer, Uterine,Cervical Cancers,Cervical Neoplasm,Cervical Neoplasm, Uterine,Cervix Neoplasm,Neoplasm, Cervix,Neoplasm, Uterine Cervical,Uterine Cervical Cancers,Uterine Cervical Neoplasm
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000230 Adenocarcinoma A malignant epithelial tumor with a glandular organization. Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective

Related Publications

A Gadducci, and M Ferdeghini, and S Cosio, and C Annicchiarico, and A Fanucchi, and C Prontera, and R Bianchi, and A R Genazzani
The Serum Assay of Soluble CD44 Standard, CD44 Variant 5, and CD44 Variant 6 in Patients with Gastric Cancer.
February 2003, Cancer research and treatment,
A Gadducci, and M Ferdeghini, and S Cosio, and C Annicchiarico, and A Fanucchi, and C Prontera, and R Bianchi, and A R Genazzani
Concentration of soluble CD44 standard and soluble CD44 variant V5 in the serum of patients with malignant bone tumors.
January 2003, Medical and pediatric oncology,
A Gadducci, and M Ferdeghini, and S Cosio, and C Annicchiarico, and A Fanucchi, and C Prontera, and R Bianchi, and A R Genazzani
Soluble CD44 v5 and v6 in serum of patients with breast cancer. Correlation with expression of CD44 v5 and v6 variants in primary tumors and location of distant metastasis.
January 1998, Breast cancer research and treatment,
A Gadducci, and M Ferdeghini, and S Cosio, and C Annicchiarico, and A Fanucchi, and C Prontera, and R Bianchi, and A R Genazzani
Increased serum levels of soluble CD44 standard, but not of variant isoforms v5 and v6, in B cell chronic lymphocytic leukemia.
January 1997, Leukemia,
A Gadducci, and M Ferdeghini, and S Cosio, and C Annicchiarico, and A Fanucchi, and C Prontera, and R Bianchi, and A R Genazzani
Evaluation of soluble CD44 splice variant v5 in the diagnosis and follow-up in breast cancer patients.
January 1997, Experimental and clinical immunogenetics,
A Gadducci, and M Ferdeghini, and S Cosio, and C Annicchiarico, and A Fanucchi, and C Prontera, and R Bianchi, and A R Genazzani
Expression of CD44 standard and variant isoforms v5, v6 and v7 in human ovarian cancer cell lines.
January 1997, Anticancer research,
A Gadducci, and M Ferdeghini, and S Cosio, and C Annicchiarico, and A Fanucchi, and C Prontera, and R Bianchi, and A R Genazzani
Soluble CD44 standard, CD44 variant 5 and CD44 variant 6 and their relation to staging in head and neck cancer.
April 2005, Acta oto-laryngologica,
A Gadducci, and M Ferdeghini, and S Cosio, and C Annicchiarico, and A Fanucchi, and C Prontera, and R Bianchi, and A R Genazzani
Serum CD44 splice variants in cervical cancer patients.
April 1995, Cancer letters,
A Gadducci, and M Ferdeghini, and S Cosio, and C Annicchiarico, and A Fanucchi, and C Prontera, and R Bianchi, and A R Genazzani
Quantitative assessment of expression of cell adhesion molecule (CD44) splice variants: CD44 standard (CD44s) and v5, v6 isoforms in oral leukoplakias: an immunohistochemical study.
January 2011, Indian journal of dental research : official publication of Indian Society for Dental Research,
A Gadducci, and M Ferdeghini, and S Cosio, and C Annicchiarico, and A Fanucchi, and C Prontera, and R Bianchi, and A R Genazzani
Levels of v5 and v6 CD44 splice variants in serum of patients with colorectal cancer are not correlated with pT stage, histopathological grade of malignancy and clinical features.
February 2004, World journal of gastroenterology,
Copied contents to your clipboard!